SG PE's close links with Hanmi on focus The PE firm has taken part in Hanmi's new businesses over the past few years
Translated by Kim So-in 공개 2020-05-27 08:00:51
이 기사는 2020년 05월 27일 08:00 thebell 에 표출된 기사입니다.
SG Private Equity (SG PE) is playing a significant role as a financial investor of South Korea’s Hanmi Pharmaceutical Group.SG PE's close relationship with Hanmi started in 2014 when the PE firm invested in Ofmom Company. Ofmom Company, 100 percent owned by Hanmi owner’s three children, was established to tap into new overseas markets. SG PE acquired Ofmom Company’s redeemable convertible preference shares (RCPS) worth 25 billion won and convertible bonds worth 25 billion won in 2014. The proceeds were used to build Ofmom Company’s new powdered formula factory in China.
Three years later, the PE firm exited its investment in convertible bonds, with Ofmom Company exercising its call options. In July 2018, SG PE sold RCPS to Ofmom Company’s affiliated company to fully exit its investments. The PE firm’s investment in Ofmom Company recorded an internal rate of return (IRR) of 11.8 percent.
Ofmom Company started to seek a new business opportunity which can create synergies with its settled powdered formula business. At that time, SG PE and Plutus Equity Partners’ acquisition of local luxury postpartum care center DeRAMA attracted CEO of Hanmi Science Lim Chong-yoon’s attention. SG PE and Plutus took over DeRAMA through a 22.5 billion won project fund, in which Lim participated as a strategic investor. Lim’s aim was to weigh the possibility of expanding its business into China by helping the postpartum care center enter the Chinese market.
DeRAMA started its business in 2016 by leasing an entire floor of Marriott Hotel in Beijing and is currently preparing to enter the Thai market. Ofmom Company has recently taken over DeRAMA from SG PE and Plutus to create strong synergies between its powdered formula business and the postpartum care business.
SG PE is likely to keep its close relationship with Hanmi, considering it has repeatedly participated in the group’s new business as a financial investor. The PE firm is currently sitting on a large pile of cash, with the firm raising 500 billion won for its third blind-pool fund at the beginning of this year.
(Reporting by Se-hun Jo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [ICTK road to IPO]경쟁자 없는 '차세대 보안칩', 2000억 후반 밸류 '정조준'
- CG인바이츠, 화일약품 지원 축소 11년 동행 '선긋기'
- [K-바이오 클러스터 기행|대전]대전 바이오 구심점, 20년 역사 바이오헬스케어협회
- 코인원, 이용규 CPO 영입…신규 서비스 출시 속도
- [코스닥 코스메틱 리뉴얼]마스크팩 잘나가던 지피클럽, 색조화장 '코디 인수'
- [K-배터리 밸류업 리포트]'오너 경영체제' 원준, 승계작업 '언제쯤'
- [thebell note]제약바이오는 다이어트 중
- [바이오텍 유증·메자닌 승부수]브릿지바이오, 유무상증자에 '대표 지분 블록딜' 왜?
- [제일약품의 온코닉테라퓨틱스 첫 '신약']성장성·사업성 갖춘 IPO 기대주 '밸류업' 이유 더 있다
- [코스닥 리빌딩 리포트]'조달 지연' 비투엔, 불성실공시법인 지정 가능성은